By David A. Sinclair – LinkedIn –
The discovery of how to safely reset cells is major focus of several well-funded startups backed by tech executives including Jeff Bezos, Sam Altman and Brian Armstrong. In 2024, Life Biosciences reported the successful restoration of visual function in primates with their drug candidate ER-100
Life Bio’s clinical trial falls under the broader umbrella of experimental therapies known as cellular rejuvenation. Life Bio’s therapy delivers Oct4, Sox2 and Klf4 “Yamanaka” proteins that our team discovered can safely reset the epigenome to a more youthful state
The goal is to rejuvenate retinal nerve cells in patients with vision loss due to glaucoma or blinded by a condition known as NAION, caused by a stroke in the back of the eye. There has been a 2-3 fold increase in the prevalence of blindness due to NAION, linked to weight loss injections
The approach is similar to a Nobel Prize–winning lab technique that can turn adult cells into stem cells, but this would be dangerous to attempt in the human body. Life Bio’s therapy is designed to stop short of that
The clinical study will be the first of its kind to attempt to reverse epigenetic aging in humans and will be performed at Harvard/Mass Eye and Ear in Boston
More at Endpoints News
https://lnkd.in/euajViuN
